Tags

Type your tag names separated by a space and hit enter

Clinical and molecular epidemiology of ciprofloxacin-susceptible MRSA encoding PVL in England and Wales.
Eur J Clin Microbiol Infect Dis 2009; 28(9):1113-21EJ

Abstract

We aimed to enhance our case ascertainment of meticillin-resistant Staphylococcus aureus encoding Panton-Valentine leucocidin (PVL-MRSA), determine the patient demographic, risk factor and disease associations, and define the clonal diversity amongst isolates referred to the UK Health Protection Agency's Staphylococcus Reference Unit. PVL-MRSA collected during 2005-6 from community-based and hospitalised patients located across England and Wales were identified by polymerase chain reaction (PCR). Representative geographically and temporally unrelated isolates were characterised via toxin gene profiling, SCCmec, spa and agr typing, multilocus sequence typing (MLST) and minimum inhibitory concentration (MIC) determinations. PVL-MRSA were identified from 275 patients. Affected individuals were <1 to 95 years of age (mean 30, median 27 years). Forty-five isolates were from 18 household or community-based clusters and 23 isolates were from outbreaks in healthcare settings. Overall, 58% (n = 161) had skin and soft tissue infections and 9% (n = 25) presented with or developed more serious disease, including eight patients (3%) with necrotising pneumonia, five of whom subsequently died. PVL-MRSA were genetically diverse and harboured SCCmecIV or V(T)/VII. Representatives of MLST clonal complexes (CCs) 8, 30 and 80 were identified the most often. The 275 PVL-MRSA included internationally disseminated community-associated MRSA (CA-MRSA) strains, as well as other minor lineages, and were associated with typical risk factors and disease presentations.

Authors+Show Affiliations

Laboratory of Healthcare Associated Infections, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom. matthew.ellington@hpa.org.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19484277

Citation

Ellington, M J., et al. "Clinical and Molecular Epidemiology of Ciprofloxacin-susceptible MRSA Encoding PVL in England and Wales." European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, vol. 28, no. 9, 2009, pp. 1113-21.
Ellington MJ, Perry C, Ganner M, et al. Clinical and molecular epidemiology of ciprofloxacin-susceptible MRSA encoding PVL in England and Wales. Eur J Clin Microbiol Infect Dis. 2009;28(9):1113-21.
Ellington, M. J., Perry, C., Ganner, M., Warner, M., McCormick Smith, I., Hill, R. L., ... Kearns, A. M. (2009). Clinical and molecular epidemiology of ciprofloxacin-susceptible MRSA encoding PVL in England and Wales. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, 28(9), pp. 1113-21. doi:10.1007/s10096-009-0757-x.
Ellington MJ, et al. Clinical and Molecular Epidemiology of Ciprofloxacin-susceptible MRSA Encoding PVL in England and Wales. Eur J Clin Microbiol Infect Dis. 2009;28(9):1113-21. PubMed PMID: 19484277.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical and molecular epidemiology of ciprofloxacin-susceptible MRSA encoding PVL in England and Wales. AU - Ellington,M J, AU - Perry,C, AU - Ganner,M, AU - Warner,M, AU - McCormick Smith,I, AU - Hill,R L, AU - Shallcross,L, AU - Sabersheikh,S, AU - Holmes,A, AU - Cookson,B D, AU - Kearns,A M, Y1 - 2009/05/30/ PY - 2009/01/29/received PY - 2009/05/10/accepted PY - 2009/6/2/entrez PY - 2009/6/2/pubmed PY - 2009/12/16/medline SP - 1113 EP - 21 JF - European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology JO - Eur. J. Clin. Microbiol. Infect. Dis. VL - 28 IS - 9 N2 - We aimed to enhance our case ascertainment of meticillin-resistant Staphylococcus aureus encoding Panton-Valentine leucocidin (PVL-MRSA), determine the patient demographic, risk factor and disease associations, and define the clonal diversity amongst isolates referred to the UK Health Protection Agency's Staphylococcus Reference Unit. PVL-MRSA collected during 2005-6 from community-based and hospitalised patients located across England and Wales were identified by polymerase chain reaction (PCR). Representative geographically and temporally unrelated isolates were characterised via toxin gene profiling, SCCmec, spa and agr typing, multilocus sequence typing (MLST) and minimum inhibitory concentration (MIC) determinations. PVL-MRSA were identified from 275 patients. Affected individuals were <1 to 95 years of age (mean 30, median 27 years). Forty-five isolates were from 18 household or community-based clusters and 23 isolates were from outbreaks in healthcare settings. Overall, 58% (n = 161) had skin and soft tissue infections and 9% (n = 25) presented with or developed more serious disease, including eight patients (3%) with necrotising pneumonia, five of whom subsequently died. PVL-MRSA were genetically diverse and harboured SCCmecIV or V(T)/VII. Representatives of MLST clonal complexes (CCs) 8, 30 and 80 were identified the most often. The 275 PVL-MRSA included internationally disseminated community-associated MRSA (CA-MRSA) strains, as well as other minor lineages, and were associated with typical risk factors and disease presentations. SN - 1435-4373 UR - https://www.unboundmedicine.com/medline/citation/19484277/Clinical_and_molecular_epidemiology_of_ciprofloxacin_susceptible_MRSA_encoding_PVL_in_England_and_Wales_ L2 - https://dx.doi.org/10.1007/s10096-009-0757-x DB - PRIME DP - Unbound Medicine ER -